Prospective Systematic Screening for Transthyretin Amyloid Cardiomyopathy in Cardiology Inpatients With Left Ventricular Hypertrophy: the IMPACT Study.

Authors

Benjamin Alos, Elsa Beard, Benjamin Khalifa, Thierry Rosenberg, Pierre-Jean Saulnier, Céline Boucher, Lisa Durocher, Michèle Grosdenier, Maxime Doublet, Matthieu Proust, Luc-Philippe Christiaens, Stéphanie Ragot, Claire Bouleti

Published in

European heart journal. Cardiovascular Imaging. Sep 15, 2026. Epub Sep 15, 2026.

Abstract

Transthyretin cardiac amyloidosis (ATTR-CM) is an underdiagnosed severe cardiomyopathy in older adults. Current diagnostic strategies rely on clinical "red flags", but data on systematic screening in minimally selected populations remain limited. We aimed to describe the prevalence of ATTR-CM among cardiology inpatients with left ventricular hypertrophy (LVH) and to identify parameters associated with its diagnosis.
This prospective single-center study included consecutive patients aged ≥60 years hospitalized in cardiology with echocardiographic LVH (wall thickness ≥12 mm), irrespective of etiology. Patients with known amyloidosis, prior heart transplantation, or contraindication to scintigraphy were excluded. All patients underwent immunologic testing and technetium-99m scintigraphy. ATTR-CM was diagnosed by cardiac uptake (Perugini grade ≥2) without significant monoclonal gammopathy. Multivariable logistic regression identified independent associations and receiver-operating characteristic curve analysis assessed diagnostic performance. Between October 2021 and June 2023, ATTR-CM was diagnosed in 29 of 400 patients (7.3%). Four variables were independently associated with ATTR-CM: basal longitudinal strain (BLS) (odds ratio [OR] 0.84, 95% CI 0.74-0.95), non-sinus rhythm (OR 3.85, 95% CI 1.30-11.11), bilateral carpal tunnel syndrome (OR 3.48, 95% CI 1.09-11.14), and history of stroke (OR 8.67, 95% CI 2.65-28.34). BLS showed the highest discrimination for ATTR-CM (AUC 0.81). During a median follow-up of 3.31 years, all-cause mortality did not significantly differ between ATTR-CM and non-ATTR-CM patients (p=0.137).
In a minimally selected cardiology population with LVH, systematic screening identified a substantial prevalence of ATTR-CM. BLS may help prioritize diagnostic testing in routine practice and facilitate earlier identification and management of ATTR-CM.

PMID:
42740647
Bibliographic data and abstract were imported from PubMed on 15 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.